A significant decrease in LMP2 60HH frequency emerged in female MS patients carrying the HLA-A*02 allele (e.g. LMP2 60HH vs RR: p  =  0.005; OR  =  0.443; 95% CI  =  0.249 – 0.790) (Table 2) but not in HLA-A*02-positive male MS patients (Table 3) nor in HLA-A*02-negative female and male MS patients (data not shown). This evidence concerns the gene HLA-A and myeloid sarcoma.